Eton Pharmaceuticals Stock (NASDAQ: ETON)

Eton Pharmaceuticals (NASDAQ:ETON) Stock, Quote.Headers.trade-ideas

Eton Pharmaceuticals

Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

AAOI

AIXI

AMPX

AMRS

APLS

APYX

ARCE

BCEL

BENF

BSAQ

BTDR

BURU

CANO

CLSK

CWCO

ERAS

ETON

EVLV

FWRD

GNLX

GRPN

HLLY

MicroCloud Hologram Inc. - Ordinary Shares

HOLO

IMPP

INOD

IONQ

JYNT

LPSN

LQDA

LTRY

Maxeon Solar Technologies, Ltd. - Ordinary Shares

MAXN

MGIH

MODV

MOGO

MRNS

NOTV

OPGN

OUST

PEGY

PSTV

PTRA

RGTI

SHCO

SLND

SMCI

SMLR

SNCE

TNGX

TSAT

TUSK

TWOU

VIRI

YTEN

Gainers


	Amyris, Inc.  (NASDAQ: AMRS) shares jumped 179.1% to $0.1839. Amyris shares dipped over 80% on Thursday after the company announced it filed for Chapter 11 bankruptcy.


Why Maxeon Solar Technologies Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Friday&#39;s Mid-Day Session

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

BLND

DESP

FFWM

GRNT

HWKN

SAGE

SMWB

U.S. stocks traded mixed, with the Dow Jones gaining around 80 points on Friday. Here are some big stocks recording gains in today’s session.

Consolidated Water, Spectrum Brands, Arco Platform, Semler Scientific And Other Big Stocks Moving Higher On Friday

Pre-Market Outlook

ACHR

EFSH

MTNB

PHXM

SNMP

TOMZ

VVOS

Gainers


	Amyris, Inc.  (NASDAQ: AMRS) shares surged 45.4% to $0.0958 in pre-market trading. Amyris shares dipped over 80% on Thursday after the company announced it filed for Chapter 11 bankruptcy.


Why Semler Scientific Shares Are Trading Higher By 40%; Here Are 20 Stocks Moving Premarket

Eton Pharmaceuticals, Inc. - Common Stock

Eton Pharmaceuticals Inc

RBC Capital analyst Drew McReynolds maintains BCE (TSX:<a class="ticker" href="https://www.benzinga.com/stock/BCE#TSX">BCE</a>) with a Sector Perform and raises the price target from C$51 to C$53.

Price Target

Analyst Ratings

TSX:BCE

RBC Capital Maintains Sector Perform on BCE, Raises Price Target to C$53

Roth MKM analyst Eric Handler maintains Electronic Arts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EA#NASDAQ">EA</a>) with a Neutral and maintains $154 price target.

Roth MKM Maintains Neutral on Electronic Arts, Maintains $154 Price Target

A six-figure campaign event at a luxury Georgia resort aimed at <a href="https://www.benzinga.com/topic/florida-cannabis" target="_blank" rel="noopener">opposing Florida's cannabis</a> and abortion amendments ended up losing money rather than generating a profit.
What Happened: The Ron <a href="https://www.benzinga.com/markets/cannabis/24/06/39279951/desantis-new-freedom-fund-has-2-stated-goals-defeat-cannabis-legalization-and-abortion-amendment">DeSantis-affiliated Florida Freedom Fund</a>, formed in late-May with the stated goal of defeating cannabis legalization and restoring abortion access, "blew through nearly $116,000 between Aug. 31 and Sept. 6, even though it raised just over $41,000 in the same time," <a href="https://floridapolitics.com/archives/696216-ron-desantis-tied-committee-spends-big-on-georgia-ritz-carlton-retreat-as-it-fights-pot-abortion-initiatives-in-florida/">reported</a> Florida Politics. Most of that, about $115,000, went to cover costs at the Ritz-Carlton in Georgia. This spending constitutes over a third of the campaign's total expenditures since it launched. 
The cannabis legalization initiative, known as Amendment 3, is set to go before Florida voters in <a href="https://www.benzinga.com/markets/cannabis/24/04/38034138/florida-supreme-court-approves-cannabis-legalization-proposal-for-november-election-in-blow-to-d" target="_blank" rel="noopener">the upcoming November elections</a>.
Despite the lavish spending, the committee raised just over $41,000 during the same period, marking the second time its expenditures outpaced contributions. Both the Florida Freedom Fund and Keep Florida Clean, another anti-amendment group linked to DeSantis, have struggled with more spending than fundraising since September. Keep Florida Clean spent more than $286,000 in the same period but raised just $1,600.
<ul>
<li>Get Benzinga&#8217;s exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you&#8217;re serious about the business, you can&#8217;t afford to miss out.</li>
</ul>
<h2 class="wp-block-heading">Pro-Cannabis Committee Is Flush: Millions Keep Coming In</h2>
Meanwhile, Amendment 3, which is now the best-funded cannabis legalization amendment in American history, has no shortage of cash on hand. Led by the <a href="https://drupal-cloudfront.benzinga.com/topic/smart-safe-florida">Smart &amp; Safe Florida</a> committee, the amendment received $90.44 million through Aug. 30, <a href="https://news.ballotpedia.org/2024/09/18/florida-amendment-3-exceeds-previous-records-for-marijuana-legalization-campaign-contributions/">according to Ballotpedia</a>.
As of Sept. 6, Florida's largest medical marijuana company, Trulieve Cannabis Corp (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TCNNF#OTC">TCNNF</a>), had contributed $87.77 million in cash and in-kind contributions to the Smart &amp; Safe committee since 2022, reported News Service of Florida, citing a state database.
DeSantis <a href="https://www.benzinga.com/markets/cannabis/24/09/40926862/desantis-targets-one-big-weed-company-funding-floridas-legalization-campaign-cites-corporate-int">lashed out</a> recently at Trulieve, calling the company a corporate monopoly that seeks to corner the cannabis market.
Read More: <a href="https://www.benzinga.com/markets/cannabis/24/09/40926862/desantis-targets-one-big-weed-company-funding-floridas-legalization-campaign-cites-corporate-int">DeSantis Targets &#8216;One Big Weed Company&#8217; Funding Florida&#8217;s Legalization Campaign, Citing &#8216;Corporate Interests&#8217;</a>
<h2 class="wp-block-heading">Anti-Cannabis Committees Having Trouble Keeping Up</h2>
Both the Florida Freedom Fund and Keep Florida Clean committees are chaired by James Uthmeier, DeSantis' chief of staff and former campaign manager when the governor ran for president. As of Sept. 6, the Florida Freedom Fund had a little more than $3.4 million remaining in cash. Keep Florida Clean had just over $3.9 million, noted Florida Politics.
While fundraising has been lackluster, the Florida Freedom Fund received several notable donations, including $25,000 from Next Generation Energy Corporation (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NGMC#OTC">NGMC</a>) and $10,000 from a Pompano Beach retiree. The outlet noted that the committee continues to rely heavily on a mid-August  $12 million donation from Citadel CEO Ken Griffin.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/09/40923340/trump-says-yes-to-legal-cannabis-in-florida-but-hometown-palm-beach-says-no-thanks-to-weed-shops">Trump Says Yes To Legal Cannabis In Florida, But Hometown Palm Beach Says No Thanks To Weed Shops</a></li>
</ul>
Photo by Hvoenok-and-GOR-Photos

Cannabis

Politics

NGMC

TCNNF

TRUL

DeSantis-Backed Anti-Cannabis PACs 'Blew Through' $116K At Fundraiser, While Pro-Pot Group Holds $90M War Chest

Guidance

Corning Says Implementing Price Increases In Display Technologies And Expects To Deliver Segment Net Income Of $900M-$950M In 2025, And To Maintain Net Income Margin Of 25%

WLDS

Wearable Devices Unveils Mudra Band Gesture Control For Apple Watch, Offering AI-Powered, Touchless Operation For Hands-Free Convenience And Enhanced Accessibility

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.corning.com%2Fworldwide%2Fen.html&amp;esheet=54124384&amp;newsitemid=20240918594823&amp;lan=en-US&amp;anchor=Corning+Incorporated&amp;index=1&amp;md5=428e64b43c9d60ea476cf7923800b0b0">Corning Incorporated</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLW#NYSE">GLW</a>) will host a meeting today at its optical fiber facility in Concord, North Carolina, with investors and industry analysts to provide significant updates to its "Springboard" plan to add more than $3 billion in annualized sales with strong incremental profit and cash flow in the next three years.
Wendell P. Weeks, chairman and chief executive officer, said,"I'm very pleased with the progress we have made on our ‘Springboard' plan to add more than $3 billion in annualized sales by 2026. The plan leads to an improving return profile, with profits growing significantly faster than sales. Today, we are sharing our Springboard operating-margin target of 20% by the end of 2026."
Weeks continued, "We are implementing price increases in Display Technologies and expect to deliver segment net income of $900 million to $950 million in 2025, and to maintain net income margin of 25%. Additionally, our positive momentum in Optical Communications continues – Enterprise sales are expected to grow by more than 40% year over year in the third quarter, driven by the continued strong adoption of our generative AI products."
Ed Schlesinger, executive vice president and chief financial officer, said, "Our second-quarter results and third-quarter guidance put us well ahead of our ‘Springboard' plan run rate. In the third quarter, we continue to expect sales of $3.7 billion and EPS of $0.50 to $0.54."
Today, Corning management will lead investors through a tour of the company's – and the world's – largest and lowest cost optical-fiber production facility. During the visit, leadership will highlight the company's unique competitive advantage and industry and technology leadership – which enables Corning to capture the significant growth opportunity outlined in its Springboard plan.

Corning Provides Update On Key Milestones In 'Springboard' Plan To Add More Than $3B In Annualized Sales, And Shares Operating-Margin Target Of 20% By End Of 2026; Sees Q3 Expected Sales Of $3.7B (Est. $3.71B); And EPS Of $0.50-$0.54 (Est. $0.53)

WIIM

CRKN

Crown Electrokinetics shares are trading higher after the company announced it secured a $10 million contract for lead pipe inspection.

RBC Capital analyst Greg Pardy reiterates Imperial Oil (TSX:<a class="ticker" href="https://www.benzinga.com/stock/IMO#TSX">IMO</a>) with a Sector Perform and maintains C$99 price target.

Reiteration

TSX:IMO

RBC Capital Reiterates Sector Perform on Imperial Oil, Maintains C$99 Price Target

Contracts

Crown Electrokinetics' Element 82 Division Secures $10M Contract For Lead Pipe Inspection, Work To Begin In Late October 2024

Walmart Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) is gearing up for the holiday season with new initiatives<a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/b40931888/walmart-unveils-its-holiday-plans-with-early-shopping-deals-and-affordable-meals" rel="noreferrer noopener"> aimed at convenient shopping habits</a>.
Leading the charge is the return of its inflation-free Thanksgiving meal, now priced lower than last year, set to launch on October 14.
This year, the retailer also introduced a convenient &#8220;buy one, give one&#8221; donation feature, allowing customers to easily contribute meals to those in need.
According to Deloitte&#8217;s annual holiday retail <a target="_blank" href="https://www2.deloitte.com/us/en/pages/about-deloitte/articles/press-releases/Deloitte-Holiday-Retail-Sales-2024-2025.html" rel="noreferrer noopener">forecast</a>, holiday retail sales are expected to rise between 2.3% and 3.3% in 2024. In 2023, holiday sales had a growth rate of 4.3% during the same timeframe.
In the aftermath of COVID, the biggest retailers in the U.S. have captured a significantly larger portion of retail growth, according to a Forbes <a target="_blank" href="https://www.forbes.com/sites/jasongoldberg/2024/05/29/the-holiday-2024-shopping-season-will-be-unlike-any-other/" rel="noreferrer noopener">report </a>released in May.
The report highlighted that Walmart and Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) account for about 38% of every additional retail sales dollar, making growth difficult for most other retailers and creating considerable uncertainty.
Also Read:&nbsp;<a target="_blank" href="https://www.benzinga.com//node/40902098" rel="noreferrer noopener">Evaluating Walmart Against Peers In Consumer Staples Distribution &amp; Retail Industry</a>
&#8220;We&#8217;ve worked hard to lower prices across our most exciting assortment ever,&#8221; said Latriece Watkins, executive vice president and chief merchandising officer, Walmart U.S.
Walmart is starting holiday savings events, with the first Walmart Holiday Deals event scheduled from October 8 to October 13.
Walmart said it is also expanding its delivery services, reaching an additional 12 million households, which will provide enhanced speed and convenience for customers looking to shop from the comfort of their homes.
Earlier this week, Sam&#8217;s Club, the&nbsp;$86 billion&nbsp;division of&nbsp;Walmart, introduced a fresh workforce compensation plan, which boosted pay for close to 100,000 frontline associates and provided guidance for&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/b40900897/sams-club-reimagines-workforce-compensation-launches-new-plan-focused-on-providing-more-predictabl" rel="noreferrer noopener">longer-term financial futures</a>.
More engaged workers proved productive, offered better service, and were more likely to stay, especially as competition heated up in the retail space.
Price Action: WMT shares are trading higher by 0.08% to $79.10 premarket at last check Thursday.
Image via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/40906505/walmart-division-sams-club-raises-wages-for-hourly-associates-a-strategic-move-to-stay-ahead-in-" target="_blank" rel="noreferrer noopener">Walmart Division Sam&#8217;s Club Raises Wages For Hourly Associates: A Strategic Move To Stay Ahead In Retail</a></li>
</ul>

Equities

Media

General

AMZN

Walmart Steps Up Holiday Game, Inflation-Free Thanksgiving Meal Returns

Roth MKM analyst Scott Searle maintains Genasys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNSS#NASDAQ">GNSS</a>) with a Buy and raises the price target from $3.5 to $4.5.

GNSS

Roth MKM Maintains Buy on Genasys, Raises Price Target to $4.5

SHEL

Shell Announces Early Participation Results And Increases Maximum Old Notes Accepted In Exchange Offers To $12B, Extends Early Participation Premium To All Holders Until October 3, 2024

APLD

ARBK

BITF

BTBT

CIFR

COIN

FUFU

HIVE

IREN

MARA

MSTR

RIOT

WULF

Shares of crypto-linked stocks are trading higher after the Fed's Wednesday decision to cut rates by 50 basis points.

On CNBC's &#8220;Mad Money Lightning Round,&#8221; Jim Cramer said Wells Fargo &amp; Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFC#NYSE">WFC</a>) is going to go higher, adding that <a href="https://www.benzinga.com/quote/WFC">it's a &#8220;winner.&#8221;</a>
On Sept. 17, the San Francisco-based bank launched specialized Application Programming Interfaces (APIs) for its Commercial Banking clients, expanding its API portfolio. 
These APIs offer real-time data access aimed at boosting sales, improving liquidity, reducing credit risk, and cutting expenses for floorplan and channel finance clients <a href="https://www.benzinga.com/markets/equities/24/09/40903846/wells-fargo-launches-new-apis-to-boost-efficiency-and-productivity-details">across several industries.</a>
&#8220;It's had too big a move up,&#8221; Cramer said when asked about Iron Mountain Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IRM#NYSE">IRM</a>). &#8220;Let's move on.&#8221;
On Aug. 1, Iron Mountain reported better-than-expected second-quarter financial results and issued FY24 AFFO guidance above estimates. Also, the company increased its quarterly dividend.
Palantir Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) is a &#8220;cold&#8221; stock, Cramer said.
On Sept. 17, the company inked a multi-year, multi-million-dollar contract with Nebraska Medicine. As per the deal, Palantir will utilize its Artificial Intelligence Platform (AIP) to enhance healthcare through <a href="https://www.benzinga.com/markets/equities/24/09/40898997/palantirs-ai-powers-nebraska-medicine-inks-multi-million-dollar-deal-to-advance-patient-care">transformative technologies</a>.
The &#8220;Mad Money&#8221; host recommended buying PG&amp;E Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PCG#NYSE">PCG</a>). &#8220;That stock is a good one, rate increase or no,&#8221; he added.
On Sept. 12, B of A Securities analyst Ross Fowler reinstated PG&amp;E with a Buy and announced a $24 price target.
Price Action:
<ul>
<li>Iron Mountain shares gained 0.5% to settle at $116.45 on Wednesday.</li>
<li>Wells Fargo shares fell 0.5% to close at $54.26 during the session.</li>
<li>Palantir shares fell 0.2% to close at $36.38 during Wednesday's session.</li>
<li>PG&amp;E shares fell 1.8% to settle at $19.51.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/09/40927530/coinbase-global-electronic-arts-and-2-other-stocks-executives-are-selling">Coinbase Global, Electronic Arts And 2 Other Stocks Executives Are Selling</a></li>
</ul>
Image: Wikimedia Commons

Long Ideas

PLTR

Jim Cramer: This Utilities Stock Is A Buy, Calls Wells Fargo A 'Winner'

GOLD

RGLD

SAND

SSRM

Shares of precious metals stocks are trading higher as gold and silver rise after the Fed on Wednesday cut rates by 50 basis points.

Neuronetics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STIM#NASDAQ">STIM</a>), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that additional payors have updated their TMS (transcranial magnetic stimulation) coverage to reduce access barriers for patients with major depressive disorder (MDD). This expanded access allows people to receive treatment such as the Company's NeuroStar TMS Therapy earlier in their treatment regimen. &nbsp;
Effective immediately, BlueCross BlueShield (BCBS) of North Carolina has expanded its TMS policy to cover adolescents 15 years and older, based on <a href="https://www.globenewswire.com/Tracker?data=qOjmrE7PDpP0iP9SeWY9op5d18oOTSBdwoHIgNjWAn9BzTHKJw9PTdysQO-eW_OwlcEPZmltrdKKK9KXWOYbH0guJe1aSPys58MhR2z9MpsyUuVQf30nDJt9tcdg63BOk1ofdy5n2Zww3OInMUpL_Y8tJjvwaSiZUMT9EOfhJsrKFd1MjahDQJshs_0Kj9s0Pqw_JG1TwBnpdISbSaL68ADhCfPeFL9ulYxPYeNG2OU=">recent clearance</a> from the United States Food and Drug Administration (FDA) for NeuroStar as the first and only TMS treatment authorized for this population. BCBC of North Carolina policies affect more than 2.2 million covered lives. Additionally, Louisiana Medicaid has started covering TMS for adults 18 and older, effective immediately. This is the first TMS coverage policy from Louisiana Medicaid, which has a footprint of more than 1.6 million covered lives.
 &nbsp;

Biotech

STIM

Neuronetics Announces That Additional Payors Have Updated Their TMS Coverage To Reduce Access Barriers For Patients With Major Depressive Disorder

<a href="https://www.globenewswire.com/Tracker?data=9txYGzddj5XqmkcafzxA8gN1tMoQQDSUNEVs8NM94vL9xd-NLcHOgSNon4qsstt91oexNNWCY_yUOlGuL7rPTA==">RenovoRx, Inc</a>. ("RenovoRx" or the "Company") (NASDAQ:<a href="https://www.benzinga.com/stock/RNXT#NASDAQ">RNXT</a>), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced that Ripal Gandhi, M.D., FSIR, FSVM will present at the Symposium on Clinical Interventional Oncology ("CIO") which is being held September 20-22, 2024, at the Loews Hotel in Miami Beach, Florida. Dr. Gandhi's presentation will highlight RenovoRx's TAMP (Trans-Arterial Micro-Perfusion) therapy platform for the treatment of locally advanced pancreatic cancer ("LAPC") and recent publications of clinical data.
Dr. Gandhi, professor of Interventional Radiology at the Miami Cancer Institute and Miami Cardiac and Vascular Institute, Florida International University Herbert Wertheim College of Medicine, is a Course Director for the Symposium on CIO. Since 2018, Dr. Gandhi has been instrumental as a principal investigator for the Miami Cancer Institute in RenovoRx's pivotal ongoing Phase III TIGeR-PaC clinical trial in LAPC.
Dr. Gandhi's presentation will&nbsp;provide an overview of the clinical challenges of the standard of care treatment available to LAPC patients. Systemic (intravenous) chemotherapy, while considered the standard-of-care for LAPC, is often associated with debilitating side effects, and may have limited effectiveness in treating this type of cancer due to tumors lacking dedicated blood vessels critical for delivering chemotherapy. Dr. Gandhi will highlight the TAMP therapy platform and the opportunity it may give to LAPC patients as a potential targeted oncology option for treatment.
Dr. Gandhi will also discuss the status of the Company's ongoing Phase III TIGeR-PaC study, which is evaluating the use of the TAMP therapy platform with gemcitabine HCl in patients with LAPC. Additionally, he will review a recent publication in the international peer-reviewed journal, The Oncologist&#xAE;, of early-stage clinical data on the intra-arterial administration of gemcitabine HCl utilizing the TAMP including Phase I/II dose escalation safety study (RR1) and acquired data from a post-marketing post-treatment observational registry study (RR2).

RNXT

RenovoRx Announces Presentation At Symposium On Clinical Interventional Oncology Highlighting TAMP For Targeted Treatment Of Locally Advanced Pancreatic Cancer On Saturday, September 21, 2024

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5e60ff475f2b9b000113c537/adam-maeder">Piper Sandler analyst Adam Maeder</a> initiated coverage on Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) with an Overweight rating and announced a price target of $131. Abbott shares fell 2.8% to close at $114.88 on Wednesday. <a href="https://www.benzinga.com/quote/ABT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Roth MKM analyst Scott Fortune initiated coverage on Turning Point Brands, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPB#NYSE">TPB</a>) with a Buy rating and announced a price target of $50. Turning Point Brands shares gained 0.9% to close at $39.03 on Wednesday. <a href="https://www.benzinga.com/quote/TPB/analyst-ratings">See how other analysts view this stock.</a></li>
<li>R<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/641c1355c9c7840001d30a8f/james-rollyson">aymond James analyst James Rollyson</a> initiated coverage on Helix Energy Solutions Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLX#NYSE">HLX</a>) with a Strong Buy rating and announced a price target of $14. Helix Energy shares fell 1.8% to close at $9.84 on Wednesday. <a href="https://www.benzinga.com/quote/HLX/analyst-ratings">See how other analysts view this stock.</a></li>
<li>RBC Capital analyst Jonathan Atkin initiated coverage on Charter Communications, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHTR#NASDAQ">CHTR</a>) with a Sector Perform rating and announced a price target of $345. Charter Communications shares gained 0.1% to close at $339.64 on Wednesday. <a href="https://www.benzinga.com/quote/CHTR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Mizuho analyst William Janela initiated coverage on Northern Oil and Gas, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOG#NYSE">NOG</a>) with an Outperform rating and announced a price target of $47. Northern Oil &amp; Gas shares rose 0.3% to close at $36.17 on Wednesday. <a href="https://www.benzinga.com/quote/NOG/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying ABT stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="512" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/19083945/image-154-1024x512.png" alt="" class="wp-image-556133" style="width:656px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/19083945/image-154-1024x512.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/19083945/image-154-300x150.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/19083945/image-154-768x384.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/19083945/image-154.png 1325w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/09/40925678/fedex-gears-up-for-q1-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-an">FedEx Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>

Initiation

CHTR

This Abbott Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

RZLV

Watching Rezolve AI; Shares Spike Higher As Co Issues PR Applauding The Recent Announcement By Microsoft And BlackRock To Invest $30B Into AI Infrastructure

Offerings

CRMT

America's Car-Mart Prices Public Offering Of 1.7M Shares At $43 Per Share, With Option For Additional 255K Shares; Proceeds To Repay Credit Facilities And Fund Corporate Purposes

Craig-Hallum analyst Chase Knickerbocker maintained a Buy rating on Eton Pharmaceuticals (ETON – Research Report) today. The company's shares close...

Craig-Hallum Reaffirms Their Buy Rating on Eton Pharmaceuticals (ETON)

Eton gains as rare disease therapy undergoes FDA review

In a report released today, Chase Knickerbocker from Craig-Hallum maintained a Buy rating on Eton Pharmaceuticals (ETON – Research Report). The com...

Craig-Hallum Sticks to Its Buy Rating for Eton Pharmaceuticals (ETON)

Eton Pharmaceuticals (ETON) Receives a Buy from Craig-Hallum

Eton Pharmaceuticals GAAP EPS of -$0.12 misses by $0.05, revenue of $9.07M beats by $0.27M

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Eton Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/eton-stock-quote/">ETON</a>) just reported results for the second quarter of 2024.<ul><li>Eton Pharmaceuticals reported earnings per share of -12 cents. This was below the analyst estimate for EPS of -7 cents.</li><li>The company reported revenue of $9.07 million.</li><li>This was 3.47% worse than the analyst estimate for revenue of $9.40 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/eton-stock-earnings-eton-pharmaceuticals-for-q2-of-2024/">ETON Stock Earnings: Eton Pharmaceuticals Misses EPS, Misses Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

ETON Stock Earnings: Eton Pharmaceuticals Misses EPS, Misses Revenue for Q2 2024

Eton Pharmaceuticals, Inc. (ETON) Q2 2024 Earnings Call Transcript

Eton Pharmaceuticals (ETON) has received a new Buy rating, initiated by H.C. Wainwright analyst, Swayampakula Ramakanth. Swayampakula Ramakanth has...

Eton Pharmaceuticals: A Strong Buy on Niche Market Leadership and Robust Growth Prospects

Harrow: Three Business Models, One Mission

Harrow: 3 Business Models, One Mission

HROW

HROWL

HROWM

MELT

Press Releases

Relief Therapeutics Enters into Exclusive U.S. License and Supply Agreement with Eton Pharmaceuticals for PKU GOLIKE

Eton Pharmaceuticals to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024

Health Care

Legal

Eton Pharmaceuticals Announces Submission to FDA of New Drug Application for ET-400 (Hydrocortisone Oral Solution)

Eton Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference

Earnings

Eton Pharmaceuticals Reports First Quarter 2024 Financial Results

Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-400 (Hydrocortisone Oral Solution)

SWK Holdings Highlights Recent Achievements and Provides Portfolio Update

Eton Pharmaceuticals to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Eton Pharmaceuticals

Eton Pharmaceuticals (ETON) Forecast

Eton Pharmaceuticals (NASDAQ:ETON) Stock, Quote.Headers.trade-ideas